| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 28, 2005
Accepted on January 23, 2006
Laboratory for Experimental Medicine and Endocrinology, Katholieke Universiteit Leuven, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium
* To whom correspondence should be addressed. E-mail: Johan.Swinnen{at}med.kuleuven.be.
The cellular effects of androgens are mediated by a cognate receptor, the androgen receptor (AR). Typically, the AR is viewed to exert its activity by binding to Androgen Response Elements (AREs) located in or near the promoter region of target genes, thereby directly affecting the expression of these genes. However, increasing evidence indicates that androgens may also indirectly influence the expression of genes that do not contain AREs by modulating the activity of secondary transcription factors, mediating the expression of growth factors acting in a paracrine or autocrine fashion or by inducing changes in the production of other hormones. These indirect effects of androgens can induce cascade-like actions and may play an important role in more complex processes involving coordinated responses of genes, cells and organs. Previously, our laboratory has identified and characterized a novel indirect mechanism of androgen action involving proteolytical activation of the key lipogenic transcription factor Sterol Regulatory Element Binding Protein (SREBP), resulting in the coordinate up-regulation of entire cellular lipogenic pathways. Interestingly, activation of SREBPs by androgens occurs not only under normal physiological conditions, but has also been observed in a growing number of pathologies, and more in particular in the setting of steroid-regulated cancers, where increased lipogenesis has been shown to have remarkable diagnostic and prognostic potential and is considered a prime target for novel therapeutic approaches. This review aims to analyze current insights into the molecular mechanism(s) underlying androgen activation of the SREBP pathway and to ascertain the extent to which this phenomenon can be generalized to androgen-responsive cell systems.
NURSA Molecule Pages Link:
This article has been cited by other articles:
 |
|
 |
|
  J. H. Suh, E.-Y. Gong, J. B. Kim, I.-K. Lee, H.-S. Choi, and K. Lee Sterol Regulatory Element-Binding Protein-1c Represses the Transactivation of Androgen Receptor and Androgen-Dependent Growth of Prostatic Cells Mol. Cancer Res., February 1, 2008; 6(2): 314 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. V. Heemers, K. M. Regan, S. M. Dehm, and D. J. Tindall Androgen Induction of the Androgen Receptor Coactivator Four and a Half LIM Domain Protein-2: Evidence for a Role for Serum Response Factor in Prostate Cancer Cancer Res., November 1, 2007; 67(21): 10592 - 10599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Brusselmans, L. Timmermans, T. Van de Sande, P. P. Van Veldhoven, G. Guan, I. Shechter, F. Claessens, G. Verhoeven, and J. V. Swinnen Squalene Synthase, a Determinant of Raft-associated Cholesterol and Modulator of Cancer Cell Proliferation J. Biol. Chem., June 29, 2007; 282(26): 18777 - 18785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. V. Heemers, T. J. Sebo, J. D. Debes, K. M. Regan, K. A. Raclaw, L. M. Murphy, A. Hobisch, Z. Culig, and D. J. Tindall Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells Cancer Res., April 1, 2007; 67(7): 3422 - 3430. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
